Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/185037
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Clèries Soler, Ramon | - |
dc.contributor.author | Buxó, Maria | - |
dc.contributor.author | Vilardell, Mireia | - |
dc.contributor.author | Ameijide, Alberto | - |
dc.contributor.author | Martínez, José Miguel | - |
dc.contributor.author | Font, Rebeca | - |
dc.contributor.author | Marcos Gragera, Rafael | - |
dc.contributor.author | Puigdemont, Montserrat | - |
dc.contributor.author | Viñas, Gemma | - |
dc.contributor.author | Carulla, Marià | - |
dc.contributor.author | Espinàs Piñol, Josep Alfons | - |
dc.contributor.author | Galceran, Jaume | - |
dc.contributor.author | Izquierdo i Font, Àngel Xavier | - |
dc.contributor.author | Borràs, Josep Maria | - |
dc.date.accessioned | 2022-04-19T13:21:38Z | - |
dc.date.available | 2022-04-19T13:21:38Z | - |
dc.date.issued | 2022-03-18 | - |
dc.identifier.issn | 1660-4601 | - |
dc.identifier.uri | http://hdl.handle.net/2445/185037 | - |
dc.description.abstract | Breast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patients diagnosed with Stages I to III BC (N = 2297). Since sample size is an issue for estimating age- and stage-specific survival indicators, we developed a method, ComSynSurData, for generating a large synthetic dataset (SynD) through probabilistic graphical modeling of the original cohort. We derived population-based survival indicators using a Bayesian relative survival model fitted to the SynD. Our modeling showed that hormone-receptor-positive BC patients diagnosed beyond 49 years of age at Stage I or beyond 59 years at Stage II do not have 10-year EM if they follow the prescribed ET regimen. This result calls for developing interventions to promote adherence to ET in patients with hormone receptor-positive BC and in turn improving cancer survival. The presented methodology here demonstrates the potential use of probabilistic graphical modeling for generating reliable synthetic datasets for validating population-based survival indicators when sample size is an issue. | - |
dc.format.extent | 17 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijerph19063605 | - |
dc.relation.ispartof | International Journal of Environmental Research and Public Health, 2022, vol. 19, num. 6 | - |
dc.relation.uri | https://doi.org/10.3390/ijerph19063605 | - |
dc.rights | cc by (c) Clèries Soler, Ramon et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Endocrinologia | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Endocrinology | - |
dc.title | No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 723021 | - |
dc.date.updated | 2022-04-19T10:50:49Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35329292 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ijerph-19-03605.pdf | 1.93 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License